핵의학 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Nuclear Medicine Market Growth & Trends:

The global nuclear medicine market size is expected to reach USD 34.51 billion by 2030, registering a CAGR of 10.16% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

Nuclear Medicine Market Report Highlights:

• By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
• The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
• By application, the oncology segment dominated the market in 2024.
• North America dominated the market with a share of 42.87% in 2024, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
• The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Nuclear Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
    • 3.2.1.2. Increasing application of radiopharmaceuticals/nuclear medicine
    • 3.2.1.3. Growing demand for accurate diagnostic methods
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Stringent regulations pertaining to production, storage, & usage
• 3.3. Nuclear Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis

• 4.1. Global Nuclear Medicine Market: Product Dashboard
• 4.2. Global Nuclear Medicine Market: Product Movement Analysis
• 4.3. Global Nuclear Medicine Market By Product, Revenue
• 4.4. Diagnostics
  • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. SPECT
    • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. TC-99m
      • 4.4.2.2.1. TC-99m market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. TL-201
      • 4.4.2.3.1. TL-201 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. GA-67
      • 4.4.2.4.1. GA-67 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.5. I-123
      • 4.4.2.5.1. I-123 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.6. Others
      • 4.4.2.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. PET
    • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.2. F18
      • 4.4.3.2.1. F18 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.3. SR-82/RB-82
      • 4.4.3.3.1. SR-82/RB-82 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.4. PYLARIFY (piflufolastat F 18)
      • 4.4.3.4.1. PYLARIFY (piflufolastat F 18) markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.5. Illuccix (gallium Ga 68 gozetotide)
      • 4.4.3.5.1. Illuccix (gallium Ga 68 gozetotide)s market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.6. Others
      • 4.4.3.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Therapeutics
  • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Alpha Emitters
    • 4.5.2.1. Alpha emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. RA-223
      • 4.5.2.2.1. RA-223 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. Others
      • 4.5.2.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Beta Emitters
    • 4.5.3.1. Beta emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.2. I-131
      • 4.5.3.2.1. I-131 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.3. Y-90
      • 4.5.3.3.1. Y-90 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.4. SM-153
      • 4.5.3.4.1. SM-153 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.5. Re-186
      • 4.5.3.5.1. Re-186 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.6. Lu-177
      • 4.5.3.6.1. Lu-177 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.7. Others
      • 4.5.3.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Brachytherapy
    • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.2. Cesium-131
      • 4.5.4.2.1. Cesium-131 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.3. Iodine-125
      • 4.5.4.3.1. Iodine-125 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.4. Palladium-103
      • 4.5.4.4.1. Palladium-103 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.5. Iridium-192
      • 4.5.4.5.1. Iridium-192 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.6. Others
      • 4.5.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis

• 5.1. Global Nuclear Medicine Market: Application Dashboard
• 5.2. Global Nuclear Medicine Market: Application Movement Analysis
• 5.3. Global Nuclear Medicine Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Cardiology
  • 5.4.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. SPECT
    • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. PET
    • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Therapeutic Applications
    • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Neurology
  • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Thyroid
  • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. SPECT
    • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Therapeutic Applications
    • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Lymphoma
  • 5.8.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Bone Metastasis
  • 5.9.1. Bone metastasis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. SPECT
    • 5.9.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. Therapeutic Applications
    • 5.9.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Endocrine Tumor
  • 5.10.1. Endocrine tumor market estimates and forecasts 2018 to 2030 (USD Million)
• 5.11. Pulmonary Scans
  • 5.11.1. Pulmonary scans market estimates and forecasts 2018 to 2030 (USD Million)
• 5.12. Urology
  • 5.12.1. Urology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.13. Others
  • 5.13.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis

• 6.1. Global Nuclear Medicine Market: End Use Dashboard
• 6.2. Global Nuclear Medicine Market: End Use Movement Analysis
• 6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Diagnostic Centers
  • 6.5.1. Diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. GE Healthcare.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Jubilant Life Sciences Ltd
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Nordion (Canada), Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bracco Imaging S.P.A
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. The Institute for Radioelements (IRE)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. NTP Radioisotopes SOC Ltd.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. The Australian Nuclear Science and Technology Organization
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. EczacIbasI-Monrol
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Lantheus Medical Imaging, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Eckert & Ziegler.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Mallinckrodt.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
  • 8.3.15. Cardinal Health.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives